Advertisement

Topics

Latest "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Stories

23:35 EST 12th February 2016 | BioPortfolio

Here are the most relevant search results for "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" found in our extensive news archives from over 250 global news sources.

More Information about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about autologous Epstein Barr virus transformed lymphoblastoid cell vaccine for you to read. Along with our medical data and news we also list autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Clinical Trials, which are updated daily. BioPortfolio also has a large database of autologous Epstein Barr virus transformed lymphoblastoid cell vaccine Companies for you to search.

Showing "autologous Epstein Barr virus transformed lymphoblastoid cell vaccine" News Articles 1–25 of 13,000+

Extremely Relevant

Prolonged Cell Division Arrest Prevents Development of Cancers Caused by Epstein-Barr Virus

A mechanism has been identified that helps explain why despite most people having been infected with Epstein-Barr virus, very few...


NIH-developed Epstein-Barr virus vaccine elicits potent neutralizing antibodies in animals

(NIH/National Institute of Allergy and Infectious Diseases) NIAID researchers and their collaborators have developed an experimental, nanoparticle-based vaccine against Epstein-Barr virus (EBV) that can induce potent neutralizing antibodies in vaccinated mice and nonhuman primates. Microscopic particles, known as nanoparticles, are being investigated as potential delivery vehicles for vaccines. Th...

Epstein-Barr virus vaccine elicits potent neutralizing antibodies in animals

Researchers from the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, and their collaborators have developed an experimental, nanoparticle-based vaccine against Epstein-Barr virus (EBV) that can induce potent neutralizing antibodies in vaccinated mice and nonhuman primates. Microscopic particles, known as nanoparticles, are being investigate...


Epstein-Barr virus envelope glycoprotein gp350 (BLLF1); ferritin

Mouse studies suggest vaccine nanoparticles engineered to display the

Enzyme Proves Viable Drug Target for Epstein-Barr Virus Infections in Duncan's Disease Patients

For certain genetic disorders, an infection can trigger an overly aggressive immune response that does more harm than good to the patient. New research suggests that targeting a single enzyme could put the brakes on a lethal immune response triggered by Epstein-Barr virus (EBV) in patients with X-linked lymphoproliferative disease (XLP-1). The

Grand Challenge two: wipe out cancers caused by the Epstein-Barr Virus

We explore the second of our Grand Challenges and ask the experts if we can wipe out cancers caused by the Epstein-Barr Virus.

The long‐lasting love affair between the budding yeast Saccharomyces cerevisiae and the Epstein‐Barr virus

The Epstein‐Barr gammaherpesvirus (EBV) is the first oncogenic virus discovered in human. Indeed, EBV has been known for more than 50 years to be tightly associated with certain human cancers. As such, EBV has been the subject of extensive studies aiming at deciphering various aspects of its biological cycle, ranging from the regulation of its genome replication and maintenance to the induction ...

Immunotherapy for Epstein-Barr related lymphomas

(University of Montreal) Health Canada recently approved, for the first time in Canada, a clinical project for a Phase I study aimed at treating lymphomas associated with the Epstein-Barr virus through adoptive cellular immunotherapy that is specific to EBV. By adapting methods initially developed in the US, the project is designed to help restore the ability of immune-compromised patients to figh...

Disrupting cell's supply chain freezes cancer virus

(Duke University) The cancer-causing Epstein-Barr virus tricks B-Cells of the human immune system into rapid cell division. To satisfy demand for more building parts, host cells will chew up their insides to free up more amino acids, fats and nucleotides. The virus also switches the cell's source of fuel to keep division going. A Duke team finds that cutting off the supply chain puts the cell in a...

Epstein-Barr Virus Not Linked To Arthritis: New Review (CME/CE)

(MedPage Today) -- EBV-immune disorders link still unclear

Atara Bio Receives FDA Orphan Drug Designation for EBV-CTL to Treat Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disorder (EBV-PTLD)

SOUTH SAN FRANCISCO, Calif., Feb. 08, 2016 (GLOBE NEWSWIRE) -- Atara Biotherapeutics, Inc. (Nasdaq:ATRA), a biopharmaceutical company focused on developing meaningful therapies for patients with severe and life-threatening diseases that have been underserved by scientific innovation, today announced that the U.S. Food and Drug Administration (FDA) granted orphan drug designation for the Compa...

Medical News Today: Drug shows promise for halting cancer virus

Scientists have discovered they can use the drug rapamycin to freeze the advance of cancer-causing Epstein-Barr virus in cells by putting the cells into a dormant state.

Epstein-Barr Viral Infections - Pipeline Review, H2 2015

Recently added to the BioPortfolio report store, Epstein-Barr Viral Infections - Pipeline Review, H2 2015 is a new report from Global Markets Direct published on 2015-08-30. This 59-page report is available in PDF from $2000. Epstein-Barr Viral Infections - Pipeline Review, H2 2015 Summary Global Markets Direct’s, ‘Epstein-Barr Viral Infections - Pipeline Review, H2 2015’, provides an over...

Study shows that certain herpes viruses can infect human neurons

For years, researchers have noted a tantalizing link between some neurologic conditions and certain species of the herpes virus. In patients with Alzheimer's disease, multiple sclerosis, and cerebellar ataxia, among other neuropathies, the cerebrospinal fluid teems with Epstein-Barr virus (EBV). Yet, the nature of that link has remained unclear, as it has been assumed that EBV, as well as other vi...

Certain herpes viruses can infect human neurons

(University of Pennsylvania School of Medicine) A tantalizing link exists between some neurologic conditions and certain species of herpes virus. In some patients with Alzheimer's disease, multiple sclerosis, and cerebellar ataxia, among others, the cerebrospinal fluid teems with Epstein-Barr virus. Yet, the link remains unclear. It's been assumed that EBV, and viruses in the same family cannot in...

Vaccine with virus-like nanoparticles is an effective treatment for RSV

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State Univ. Their findings, published in the International Journal of Nanomedicine, suggest this vaccine induces long-term protection against RSV and could be a novel treatment option for this disease....

Explainer: what is Guillain-Barré syndrome and is it caused by the Zika virus?

Steven Maltby, University of Newcastle The recent outbreak of Zika virus in South America has been a cause of concern. This is not because Zika itself is a serious condition, but because it is believed to be linked to birth defects when expectant mothers are infected and to a rare but severe and progressive neurological […] The post Explainer: what is Guillain-Barré syndrome and is it cause...

Novel Epstein-Barr Virus Vaccines

Epstein-Barr Virus (EBV) is the causative agent of infectious mononucleosis and is associated with certain types of cancers, such as Hodgkin's lymphoma, Burkitt's lymphoma, gastric carcinoma, and nasopharyngeal carcinoma. There are currently no vaccines against EBV on the market and there is only supportive treatment available for EBV infection. The subject technologies are novel vaccine candidat...

Transcriptomic variation of pharmacogenes in multiple human tissues and lymphoblastoid cell lines

Relevant

ERCC1 SNP can identify good prognosis in nasopharyngeal CA

(HealthDay)—Excision repair cross-complementing group 1 (ERCC1) genotype for the single nucleotide polymorphism (SNP) cytosine-to-thymine substitution at codon 118 (C118T) interacts with post-radiotherapy plasma Epstein-Barr virus (EBV) DNA (pEBV) to identify favorable prognosis for a subgroup of patients with nasopharyngeal carcinoma (NPC), according to a study published in the Aug. 15 issue of...

The Oral Polio Vaccine Can Go ‘Feral,’ But WHO Vows to Tame It

(NPR) – But there is a downside to the Sabin vaccine. Unlike the earlier vaccine developed by Dr. Jonas Salk and administered by injection, the oral version contains live polio virus. Under some circumstances, virus from the vaccine can spread, … Read More

Zika virus vaccine a step closer

Researchers are confident of quickly finding a vaccine for the Zika virus following the development of a vaccine for a similar mosquito-borne disease.

Vaccine With Virus-Like Nanoparticles is Effective Treatment for RSV, Study Finds

A vaccine containing virus-like nanoparticles, or microscopic, genetically engineered particles, is an effective treatment for respiratory syncytial virus (RSV), according to researchers at Georgia State University. The findings, published on July 14 in the International Journal of Nanomedicine, suggest this vaccine induces long-term protection

LYMPHOME associé au virus d'Epstein-Barr: Une nouvelle immunothérapie adoptive - UdeM

Eduquer le système immunitaire pour qu'il devienne capable de reconnaitre des maladies spécifiques et de les combattre. C'est le principe de ce projet clinique en essai de phase I visant à traiter des lymphomes associés au virus EBV (virus d'Epstein-Barr) par le biais d'une immunothérapie adoptive cellulaire spécifique contre le virus. Son objectif, redonn...

Novavax's vaccine first to protect against common respiratory virus

(Reuters) - A vaccine developed by Novavax Inc was shown to prevent a common respiratory viral infection in a mid-stage study, taking it one step closer to becoming the first vaccine for the virus that affects almost all American children.


Quick Search
Advertisement
 

News Quicklinks